^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Pancreatic Cancer)
    New
    Title:

    Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

    Excerpt:
    AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Efficacy of olaparib therapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD).

    Published date:
    05/19/2021
    Excerpt:
    ...olaparib, demonstrate clinical benefit in metastatic PDAC with BRCA mutations (mBRCA)...The medOS for mBRCA vs. HRD was 7.7 vs. 5.3 months (HR 0.7, 95% CI: 0.2-1.9, p = 0.4).
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Clin J Gastroenterol
    Title:

    Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation

    Published date:
    12/27/2022
    Excerpt:
    A 47-year-old female who was previously treated for BRCA1 germline mutant breast cancer presented with increasing back pain. Radiological and pathological investigations led to the diagnosis of pancreatic ductal adenocarcinoma with multiple hepatic metastases....Adjuvant olaparib treatment was administered with no signs of recurrence at 7 months after surgery. In conclusion, a pathologic complete response after FOLFIRINOX and olaparib maintenance treatment in hepatic metastasized pancreatic ductal adenocarcinoma is extremely rare.
    DOI:
    10.1007/s12328-022-01741-2
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Case Rep Oncol
    Title:

    Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review

    Excerpt:
    A 59-year-old female...Biopsy confirmed PDAC....A mutational test was requested and confirmed a BRCA1 germline mutation. The patient was started on olaparib. After 3 cycles, images showed a significant response and after 6 cycles, it remained stable, with persistent fall in CA19-9 levels. She is currently on treatment, with ongoing response.
    DOI:
    10.1159/000508533
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Pancreas
    Title:

    Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells

    Published date:
    02/01/2022
    Excerpt:
    One PDAC cell line, KP-2, was positive for BRCAness and was more sensitive to cisplatin and olaparib...Our results revealed that a considerable number of PDACs are positive for BRCAness, suggesting that BRCAness status could be a useful biomarker for selecting anticancer treatments for advanced or relapsed PDAC.
    Secondary therapy:
    cisplatin
    DOI:
    10.1097/MPA.0000000000001975